Objective: The objective of this study was to perform the first comprehensive, multi-jurisdictional analysis of how all 57 U.S. jurisdictions regulate intoxicating hemp-derived cannabinoids—specifically Δ⁸-tetrahydrocannabinol (Δ⁸-THC), Δ¹⁰-THC, hexahydrocannabinol (HHC), THC-O, and related isomers. This work aims to assess the legal consistency, public-health implications, enforcement challenges, and regulatory gaps that have emerged following the commercialization of intoxicating hemp products after the 2018 Farm Bill.

Methods: A structured policy analysis was conducted across **50 U.S. states, the District of Columbia, five U.S. territories (PR, GU, VI, AS, MP), and the Eastern Band of Cherokee Indians (EBCI)**. Jurisdictional rules were reviewed through official statutes, emergency regulations, published guidance, and enforcement bulletins. Regulations were classified into six categories:

1. Full prohibitions on Δ⁸/Δ¹⁰/HHC.
2. Potency-restricted sales , including per-serving and per-package limits.
3. Dispensary-only restrictions , treating intoxicating hemp as cannabis.
4. Explicitly regulated “intoxicating cannabinoid” categories with licensing and testing rules.
5. Hemp-only legality under Δ⁹-THC thresholds, without addressing isomers.
6. Fully unregulated markets, lacking testing, labeling, or age restrictions.

Additional analyses compared:
• THC-calculation models (Δ⁹-only vs. total THC)
• Potency thresholds (5 mg vs. 10 mg vs. unrestricted)
• Product-type restrictions (gummies, beverages, vapes, concentrates)
• Testing requirements
• Labeling and packaging controls
• Retail age-limits or lack thereof
• Enforcement and penalty structures
• Jurisdictions with silent or ambiguous rules

Results: The regulatory environment surrounding intoxicating hemp products is extremely fragmented and inconsistent. Approximately half of U.S. jurisdictions **fully prohibit or restrict Δ⁸/Δ¹⁰ THC** to licensed adult-use or medical cannabis dispensaries (e.g., NY, CO, MA, VT, IL, MI). Others, such as Minnesota, allow intoxicating hemp products but impose **strict potency limits** (≤5 mg THC/serving; ≤50 mg/package).

A substantial number of jurisdictions—including **North Carolina, New Jersey, New Mexico, North Dakota, Wisconsin, West Virginia, and the District of Columbia**—permit **open, unregulated sales** of Δ⁸/Δ¹⁰ products in convenience stores, gas stations, and online platforms without mandatory testing, labeling, packaging, or age minimums. Several jurisdictions (e.g., SC, UT, WY, AS) do **not address intoxicating isomers at all**, leaving legal status unclear and enforcement inconsistent.

Jurisdictions diverge significantly in THC-calculation methodology. Some apply only the **federal Δ⁹-THC ≤0.3% dry-weight threshold**, while others use **total THC formulas** (Δ⁹ + Δ⁸ + Δ¹⁰ + THCA×0.877), and still others impose **per-serving, per-container, or per-product potency rules**. This inconsistency directly affects product legality, enabling products to be legal in one jurisdiction, restricted in another, and illegal in a third.

Testing and safety standards vary dramatically: some jurisdictions require **full cannabis-panel testing**, while others have **no testing requirements whatsoever**. As a result, consumers may unknowingly purchase products containing **residual solvents, heavy metals, synthetic conversion reagents, pesticides, or inaccurate potency values**. Many intoxicating hemp products are marketed without age limits, enabling widespread youth access to psychoactive compounds.

The combined findings reveal that intoxicating hemp occupies a legal space where **hemp law, controlled substance law, and cannabis regulation collide**, creating conflicting interpretations, regulatory gaps, and a rapidly expanding gray market.

Conclusion: This analysis demonstrates that the United States lacks a coherent or unified regulatory framework for intoxicating hemp cannabinoids. While Δ⁸/Δ¹⁰ and HHC products originate from federally legal hemp, state-level responses range from strict prohibition to unrestricted commercialization.

Dr. Sherman Hom is the Director of Regulatory Affairs at Medicinal Genomics Corporation (MGC) that markets genetics-based cannabis tests and breeding technologies. At MGC, Sherman provides recommendations to cannabis regulatory agency officials that are tasked with drafting and/or modifying cannabis, hemp, and psychedelic mushroom microbial testing regulations to ensure safe products for patients and consumers. He is a member of the AOAC Cannabis Science Program, ASTM International D37 Cannabis Committee, Association of Food and Drug Officials Cannabis Committee, National Cannabis Laboratory Council, and the Colorado Public Health and Environment Cannabis Science and Policy Forum. Before MGC, he worked at the New Jersey Department of Health, Division of Public Health & Environmental Laboratories for 21+ years as a Program Manager of various clinical diagnostic testing units, which included the Cannabis Laboratory Microbial Testing Laboratory. Sherman received his B.A in Biology from the University of California at San Diego, PhD in Microbiology from the University of California at Davis, and was a Postdoctoral Fellow in Molecular Genetics at The John Hopkins University.